Sirnaomics
The company is also pushing ahead with a microRNA-replacement therapy that is designed to improve patient response to colon cancer treatment.
Sirnaomics this week released preclinical data showing that two siRNAs against different strains of human papillomavirus could halt growth of papillomas in an animal model of HPV infection.
Sirnaomics could begin phase I testing of its siRNA-based wound-healing drug candidate STP-705 as soon as next year and expects to run the trial in China, a company official told Gene Silencing News this week.
The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.
The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.
Jul 8, 2010
Jun 24, 2010
Jun 17, 2010
Jul 23, 2009
Feb 24, 2009